Graphpad prism heatmap9/26/2023 Cellular entry of SARS-CoV-2 and SARS-CoV is mediated by the viral spike glycoprotein, which forms trimeric spikes on the viral surface. All three highly pathogenic coronaviruses belong to the betacoronavirus genus: SARS-CoV-2 and SARS-CoV cluster within the sarbecovirus subgenus and originated in bats, whereas Middle East respiratory syndrome coronavirus (MERS-CoV) belongs to the merbecovirus subgenus and is transmitted to humans through dromedary camels. Effective countermeasures are urgently needed to control the pandemic and protect vulnerable populations.Ĭoronaviruses are zoonotic pathogens responsible for several epidemics and a pandemic in the past two decades ( Du et al., 2009 Li et al., 2015 Wang et al., 2016). As of 22 April 2022, SARS-CoV-2 has spread to more than 200 countries/territories and resulted in more than 6.2 million deaths (World Health Organization). ![]() These data support the development of MW3321 as a monotherapy or cocktail against SARS-CoV-2-related diseases.Īfter its emergence in December 2019, the ongoing COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has caused devastating consequences to human health and the global economy. Moreover, MW3321 exhibits a typical hIgG1 pharmacokinetic and safety profile in cynomolgus monkeys. MW3321 could effectively reduce viral burden in hACE2-transgenic mice challenged with either wild-type or Delta SARS-CoV-2 strains through viral neutralization and Fc-mediated effector functions. Escape mutation experiments using replicating SARS-CoV-2 pseudovirus show that escape mutants were not generated until passage 6 for MW3321, which is much more resistant to escape mutation compared with another clinical staged SARS-CoV-2 neutralizing mAb MW3311. MW3321 retains full neutralization activity to all tested 12 variants that have arisen in the human population, which are assigned as VOC (Variants of Concern) and VOI (Variants of Interest) due to their impacts on public health. In this work, we comprehensively characterize the breadth and efficacy of SARS-CoV-2 RBD-targeting fully human monoclonal antibody (mAb) MW3321. Neutralization antibodies targeting SARS-CoV-2 could provide immediate protection after SARS-CoV-2 infection, especially for the most vulnerable populations. Ideal SARS-CoV-2 therapeutic antibodies would have high potency in viral neutralization against several emerging variants. Therapeutics against variants of SARS-CoV-2 are urgently needed. Since the outbreak of the coronavirus disease 2019 (COVID-19) pandemic, several variants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have emerged and have consistently replaced the previous dominant variant. 4Beijing Kohnoor Science and Technology Co., Ltd., Beijing, China.3State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, Xiamen University, Xiamen, China.2Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, China.1Mabwell (Shanghai) Bioscience Co., Ltd., Shanghai, China. ![]() Wen Jiang 1 † Zherui Zhang 2 † Yuhe Zhu 3 † Ben Chen 1 Chunying Gu 1 Zhiyan Liu 1 Xukai Zhang 1 Hualong Xiong 3 Yanan Zhang 2 Bin Zheng 1 Rongjuan Wang 1,4 Shasha Jiao 1,4 An Wang 1 Tianying Zhang 3 Jinchao Zhang 1 Shuang Wang 1,4* Bo Zhang 2* Gang Li 1* Xun Gui 1*
0 Comments
Leave a Reply.AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |